Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies
Aims: The global demographic transition has led to a growing ageing population. Neurodegenerative disease prevalence is high in the elderly, as aged brains accumulate molecular and cellular damage. Protein misfolding and aggregation are pathological processes underlying neurodegeneration, as seen in...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-06-01
|
| Series: | BJPsych Open |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472425107928/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059582214242304 |
|---|---|
| author | Arzoo Dar Sharmi Bhattacharyya |
| author_facet | Arzoo Dar Sharmi Bhattacharyya |
| author_sort | Arzoo Dar |
| collection | DOAJ |
| description | Aims: The global demographic transition has led to a growing ageing population. Neurodegenerative disease prevalence is high in the elderly, as aged brains accumulate molecular and cellular damage. Protein misfolding and aggregation are pathological processes underlying neurodegeneration, as seen in dementia. This coupled with oxidative stress, disrupted ubiquitin-proteosome system and neuroinflammation may contribute to neuronal damage/death. Lewy Body dementia (LBD) collectively refers to Parkinson’s disease (PD), Parkinson-disease dementia and dementia with Lewy bodies (DLB). It is characterised by Lewy Body (LB) deposits in the central nervous system, predominantly compromised of misfolded α-synuclein protein. Disease-modifying therapy (DMT) targets underlying protein misfolding and promotes LB clearance. |
| format | Article |
| id | doaj-art-32f6b0b6c3d64a38a205c144ef4de83e |
| institution | DOAJ |
| issn | 2056-4724 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | BJPsych Open |
| spelling | doaj-art-32f6b0b6c3d64a38a205c144ef4de83e2025-08-20T02:50:52ZengCambridge University PressBJPsych Open2056-47242025-06-0111S326S32710.1192/bjo.2025.10792Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-SynucleinopathiesArzoo Dar0Sharmi Bhattacharyya1Hull York Medical School, York, United KingdomUniversity of Chester, Chester, United KingdomAims: The global demographic transition has led to a growing ageing population. Neurodegenerative disease prevalence is high in the elderly, as aged brains accumulate molecular and cellular damage. Protein misfolding and aggregation are pathological processes underlying neurodegeneration, as seen in dementia. This coupled with oxidative stress, disrupted ubiquitin-proteosome system and neuroinflammation may contribute to neuronal damage/death. Lewy Body dementia (LBD) collectively refers to Parkinson’s disease (PD), Parkinson-disease dementia and dementia with Lewy bodies (DLB). It is characterised by Lewy Body (LB) deposits in the central nervous system, predominantly compromised of misfolded α-synuclein protein. Disease-modifying therapy (DMT) targets underlying protein misfolding and promotes LB clearance.https://www.cambridge.org/core/product/identifier/S2056472425107928/type/journal_article |
| spellingShingle | Arzoo Dar Sharmi Bhattacharyya Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies BJPsych Open |
| title | Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies |
| title_full | Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies |
| title_fullStr | Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies |
| title_full_unstemmed | Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies |
| title_short | Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies |
| title_sort | dementia with lewy bodies a review of disease modifying therapies for α synucleinopathies |
| url | https://www.cambridge.org/core/product/identifier/S2056472425107928/type/journal_article |
| work_keys_str_mv | AT arzoodar dementiawithlewybodiesareviewofdiseasemodifyingtherapiesforasynucleinopathies AT sharmibhattacharyya dementiawithlewybodiesareviewofdiseasemodifyingtherapiesforasynucleinopathies |